Clinical Trial Update: Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia [Phase 2]

View source ↗

Summary

Open-label extension study of ISIS 301012 (Mipomersen) for familial hypercholesterolemia has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia

Drugs mentioned

• Mipomersen (mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant | Phase 2 | Status: COMPLETED | Results posted: 2013-04-05